ArticleHealth science reports2025

FDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy.

Laiba Jalal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.